| Market revenue in 2025 | USD 271.5 million |
| Market revenue in 2033 | USD 892.0 million |
| Growth rate | 16.1% (CAGR from 2026 to 2033) |
| Largest segment | Software |
| Fastest growing segment | Services |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Software, Services |
| Key market players worldwide | Certara Inc Ordinary Shares, Dassault Systemes SE, Avantium NV, Simulations Plus Inc, Schrodinger Inc Ordinary Shares, Chemical Computing Group, Physiomics, Rosa & Co, Genedata AG, Instem, Yokogawa Electric Corp., Immunetrics |
Germany held the dominant share of Europe biosimulation market owing to high adoption of biosimulation software to optimize R&D activities for higher productivity and greater regulatory compliance, thus enabling expedited drug discovery and development process.
Furthermore, shorter product development cycle, improved organizational effectiveness, and greater access to advanced technology are among the additional benefits provided by biosimulation.
Several prominent pharmaceutical companies have their R&D facilities in the country. Furthermore, these industry players often collaborate with academic research institutes and universities for conducting clinical trials. These benefits are expected to drive the preference for biosimulation in Germany.
Publish Date: May 29, 2026
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Certara Inc Ordinary Shares | View profile | 1,391 | 100 Overlook Center, Suite 101, Princeton, NJ, United States, 08540 | www.certara.com |
| Dassault Systemes SE | View profile | 23,811 | 10, Rue Marcel Dassault, Velizy-Villacoublay, France, 78140 | www.3ds.com |
| Avantium NV | View profile | 249 | Zekeringstraat 29-31, Amsterdam, Netherlands, 1014 BV | www.avantium.com |
| Simulations Plus Inc | View profile | 197 | 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059 | www.simulations-plus.com |
| Schrodinger Inc Ordinary Shares | View profile | 787 | 1540 Broadway, 24th Floor, New York, NY, United States, 10036 | www.schrodinger.com |
| Chemical Computing Group | View profile | 11-50 | Montreal, Quebec, Canada, North America | www.chemcomp.com |
| Physiomics | View profile | 11-50 | Oxford, Oxfordshire, United Kingdom, Europe | www.physiomics-plc.com/ |
| Rosa & Co | View profile | 11-50 | San Carlos, California, United States, North America | www.rosaandco.com |
| Genedata AG | View profile | 51-100 | Basel, Basel-Stadt, Switzerland, Europe | www.genedata.com/ |
| Instem | View profile | 51-100 | Conshohocken, Pennsylvania, United States, North America | www.instem.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimulation Market Outlook will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 67.59% in 2025.
Horizon Databook has segmented the Germany biosimulation market based on software, services covering the revenue growth of each sub-segment from 2021 to 2033.
Germany held the dominant share of Europe biosimulation market owing to high adoption of biosimulation software to optimize R&D activities for higher productivity and greater regulatory compliance, thus enabling expedited drug discovery and development process.
Furthermore, shorter product development cycle, improved organizational effectiveness, and greater access to advanced technology are among the additional benefits provided by biosimulation.
Several prominent pharmaceutical companies have their R&D facilities in the country. Furthermore, these industry players often collaborate with academic research institutes and universities for conducting clinical trials. These benefits are expected to drive the preference for biosimulation in Germany.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Biosimulation Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Biosimulation Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
